SE9903831D0 - Formulation of substituted benzimidazoles - Google Patents

Formulation of substituted benzimidazoles

Info

Publication number
SE9903831D0
SE9903831D0 SE9903831A SE9903831A SE9903831D0 SE 9903831 D0 SE9903831 D0 SE 9903831D0 SE 9903831 A SE9903831 A SE 9903831A SE 9903831 A SE9903831 A SE 9903831A SE 9903831 D0 SE9903831 D0 SE 9903831D0
Authority
SE
Sweden
Prior art keywords
sodium
formulation
potassium salt
polyethylene glycol
liquid formulations
Prior art date
Application number
SE9903831A
Other languages
English (en)
Swedish (sv)
Inventor
Mikael Bruells
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903831A priority Critical patent/SE9903831D0/xx
Publication of SE9903831D0 publication Critical patent/SE9903831D0/xx
Priority to ARP000105283A priority patent/AR029005A1/es
Priority to TW089121063A priority patent/TWI236372B/zh
Priority to IL14910700A priority patent/IL149107A0/xx
Priority to DK00973295T priority patent/DK1274427T3/da
Priority to NZ518155A priority patent/NZ518155A/en
Priority to HK03103347.1A priority patent/HK1051142B/en
Priority to RU2002110328/15A priority patent/RU2286782C2/ru
Priority to UA2002043345A priority patent/UA74347C2/uk
Priority to TR2002/01103T priority patent/TR200201103T2/xx
Priority to SI200030759T priority patent/SI1274427T1/sl
Priority to AU11823/01A priority patent/AU782866B2/en
Priority to MXPA02003900A priority patent/MXPA02003900A/es
Priority to AT00973295T priority patent/ATE304851T1/de
Priority to US09/701,714 priority patent/US6730685B1/en
Priority to DE60022789T priority patent/DE60022789T2/de
Priority to HU0203121A priority patent/HUP0203121A3/hu
Priority to SK539-2002A priority patent/SK286266B6/sk
Priority to PL354926A priority patent/PL199868B1/pl
Priority to ES00973295T priority patent/ES2246903T3/es
Priority to JP2001531388A priority patent/JP2003512327A/ja
Priority to PCT/SE2000/001992 priority patent/WO2001028558A1/en
Priority to BR0014895-4A priority patent/BR0014895A/pt
Priority to EP00973295A priority patent/EP1274427B1/en
Priority to CZ20021375A priority patent/CZ20021375A3/cs
Priority to CA2425199A priority patent/CA2425199C/en
Priority to CNB008146373A priority patent/CN1213751C/zh
Priority to EEP200200204A priority patent/EE05175B1/xx
Priority to KR1020027005112A priority patent/KR100785603B1/ko
Priority to MYPI20004932A priority patent/MY131971A/en
Priority to CO00079671A priority patent/CO5261533A1/es
Priority to BG106602A priority patent/BG65580B1/bg
Priority to IL149107A priority patent/IL149107A/en
Priority to ZA200202905A priority patent/ZA200202905B/en
Priority to IS6347A priority patent/IS2196B/is
Priority to NO20021860A priority patent/NO329545B1/no
Priority to CY20051101567T priority patent/CY1106055T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9903831A 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles SE9903831D0 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles
ARP000105283A AR029005A1 (es) 1999-10-22 2000-10-06 FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA
TW089121063A TWI236372B (en) 1999-10-22 2000-10-09 Formulation of substituted benzimidazoles
KR1020027005112A KR100785603B1 (ko) 1999-10-22 2000-10-13 치환된 벤즈이미다졸의 제제
HU0203121A HUP0203121A3 (en) 1999-10-22 2000-10-13 Pharmaceutical composition containing substituted benzimidazoles and its use
JP2001531388A JP2003512327A (ja) 1999-10-22 2000-10-13 置換ベンズイミダゾール製剤
NZ518155A NZ518155A (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
HK03103347.1A HK1051142B (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
RU2002110328/15A RU2286782C2 (ru) 1999-10-22 2000-10-13 Препарат замещенных бензимидазолов
UA2002043345A UA74347C2 (uk) 1999-10-22 2000-10-13 Безводна або майже безводна, стабільна рідка композиція
TR2002/01103T TR200201103T2 (tr) 1999-10-22 2000-10-13 İkame edilmiş benzimidazol formülasyonları
SI200030759T SI1274427T1 (sl) 1999-10-22 2000-10-13 Formulacija substituiranih benzimidazolov
AU11823/01A AU782866B2 (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
MXPA02003900A MXPA02003900A (es) 1999-10-22 2000-10-13 Formulacion de benzimidazoles sustituidos.
AT00973295T ATE304851T1 (de) 1999-10-22 2000-10-13 Zusammensetzung die substituierte benzimidazole enthält
US09/701,714 US6730685B1 (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
DE60022789T DE60022789T2 (de) 1999-10-22 2000-10-13 Zusammensetzung die substituierte benzimidazole enthält
IL14910700A IL149107A0 (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
SK539-2002A SK286266B6 (sk) 1999-10-22 2000-10-13 Stabilný kvapalinový prípravok, spôsob jeho prípravy a jeho použitie
PL354926A PL199868B1 (pl) 1999-10-22 2000-10-13 Trwały ciekły preparat inhibitora H⁺ , K⁺-ATPazy, sposób jego wytwarzania, zastosowanie glikolu polietylenowego i soli sodowej lub potasowej inhibitora H⁺ , K⁺-ATPazy oraz zastosowanie tego preparatu
ES00973295T ES2246903T3 (es) 1999-10-22 2000-10-13 Formulacion de bencimidazoles sustituidos.
DK00973295T DK1274427T3 (da) 1999-10-22 2000-10-13 Formulering af substituerede benzimidazoler
PCT/SE2000/001992 WO2001028558A1 (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
BR0014895-4A BR0014895A (pt) 1999-10-22 2000-10-13 Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais
EP00973295A EP1274427B1 (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
CZ20021375A CZ20021375A3 (cs) 1999-10-22 2000-10-13 Prostředek na bázi substituovaného benzimidazolu
CA2425199A CA2425199C (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles
CNB008146373A CN1213751C (zh) 1999-10-22 2000-10-13 取代苯并咪唑的制剂
EEP200200204A EE05175B1 (et) 1999-10-22 2000-10-13 Asendatud bensimidasooli preparaat, meetod selle valmistamiseks ja selle kasutamine meditsiinis
CO00079671A CO5261533A1 (es) 1999-10-22 2000-10-19 Formulaciones parenterales liquidas estables libres de agua que comprenden sales de sodio o potasio de bencimidazoles sustituidos y polietilenglicol
MYPI20004932A MY131971A (en) 1999-10-22 2000-10-19 Formulation of substituted benzimidazoles
BG106602A BG65580B1 (bg) 1999-10-22 2002-04-10 Течен състав със заместени бензимидазоли
IL149107A IL149107A (en) 1999-10-22 2002-04-11 Stable liquid formulations of converted benzimidazoles, a process for their preparation and use in the preparation of a drug for the treatment of gastric and intestinal diseases
ZA200202905A ZA200202905B (en) 1999-10-22 2002-04-12 Formulation of substituted benzimidazoles.
IS6347A IS2196B (is) 1999-10-22 2002-04-17 Blanda útskiptra bensimídasóla
NO20021860A NO329545B1 (no) 1999-10-22 2002-04-19 Stabil flytende formulering, fremgangsmate for fremstilling derav, samt anvendelse derav i medisin
CY20051101567T CY1106055T1 (el) 1999-10-22 2005-12-19 Τυποποιηση των υποκατεστημενων βενζιμιδαζολων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles

Publications (1)

Publication Number Publication Date
SE9903831D0 true SE9903831D0 (sv) 1999-10-22

Family

ID=20417464

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles

Country Status (35)

Country Link
US (1) US6730685B1 (enExample)
EP (1) EP1274427B1 (enExample)
JP (1) JP2003512327A (enExample)
KR (1) KR100785603B1 (enExample)
CN (1) CN1213751C (enExample)
AR (1) AR029005A1 (enExample)
AT (1) ATE304851T1 (enExample)
AU (1) AU782866B2 (enExample)
BG (1) BG65580B1 (enExample)
BR (1) BR0014895A (enExample)
CA (1) CA2425199C (enExample)
CO (1) CO5261533A1 (enExample)
CY (1) CY1106055T1 (enExample)
CZ (1) CZ20021375A3 (enExample)
DE (1) DE60022789T2 (enExample)
DK (1) DK1274427T3 (enExample)
EE (1) EE05175B1 (enExample)
ES (1) ES2246903T3 (enExample)
HU (1) HUP0203121A3 (enExample)
IL (2) IL149107A0 (enExample)
IS (1) IS2196B (enExample)
MX (1) MXPA02003900A (enExample)
MY (1) MY131971A (enExample)
NO (1) NO329545B1 (enExample)
NZ (1) NZ518155A (enExample)
PL (1) PL199868B1 (enExample)
RU (1) RU2286782C2 (enExample)
SE (1) SE9903831D0 (enExample)
SI (1) SI1274427T1 (enExample)
SK (1) SK286266B6 (enExample)
TR (1) TR200201103T2 (enExample)
TW (1) TWI236372B (enExample)
UA (1) UA74347C2 (enExample)
WO (1) WO2001028558A1 (enExample)
ZA (1) ZA200202905B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001276721A1 (en) * 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
WO2002015908A1 (en) * 2000-08-18 2002-02-28 Takeda Chemical Industries, Ltd. Injections
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
CN100558726C (zh) * 2003-02-24 2009-11-11 田边三菱制药株式会社 泰妥拉唑的对映体及其在治疗中的应用
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060089376A1 (en) * 2004-10-27 2006-04-27 Joshi Ramesh A Tenatoprazole salts and process of preparation thereof
AU2007248949B2 (en) * 2006-05-09 2010-04-08 Astrazeneca Ab Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
JP6698651B2 (ja) 2014-11-13 2020-05-27 スリーエム イノベイティブ プロパティズ カンパニー 試料中の細菌atpを検出するためのatp−ジホスホヒドロラーゼを含むキット
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2025078989A1 (en) * 2023-10-11 2025-04-17 Reena Patel Stabilized pharmaceutical compositions
WO2025181379A1 (en) * 2024-03-01 2025-09-04 Etico Lifesciences Private Limited Liquid, storage stable, directly injectable, pantoprazole formulations, their uses and manufacturing

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
DK399389A (da) 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SG52479A1 (en) 1992-07-28 1998-09-28 Astra Ab Injection and injection kit containing omeprazole and its analogs
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TW359614B (en) 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions

Also Published As

Publication number Publication date
IL149107A (en) 2008-04-13
US6730685B1 (en) 2004-05-04
IS6347A (is) 2002-04-17
MXPA02003900A (es) 2002-09-30
CY1106055T1 (el) 2011-04-06
CO5261533A1 (es) 2003-03-31
ES2246903T3 (es) 2006-03-01
PL354926A1 (en) 2004-03-22
TWI236372B (en) 2005-07-21
CA2425199C (en) 2010-12-07
CZ20021375A3 (cs) 2002-09-11
HUP0203121A3 (en) 2004-01-28
EE200200204A (et) 2003-04-15
CA2425199A1 (en) 2001-04-26
BG65580B1 (bg) 2009-01-30
KR100785603B1 (ko) 2007-12-14
BG106602A (en) 2002-12-29
HK1051142A1 (en) 2003-07-25
PL199868B1 (pl) 2008-11-28
SK5392002A3 (en) 2002-10-08
BR0014895A (pt) 2002-06-18
AR029005A1 (es) 2003-06-04
RU2286782C2 (ru) 2006-11-10
CN1213751C (zh) 2005-08-10
SK286266B6 (sk) 2008-06-06
NO329545B1 (no) 2010-11-08
HUP0203121A2 (hu) 2003-01-28
ZA200202905B (en) 2003-07-14
KR20020059637A (ko) 2002-07-13
AU1182301A (en) 2001-04-30
DK1274427T3 (da) 2005-12-27
TR200201103T2 (tr) 2002-08-21
IL149107A0 (en) 2002-11-10
EE05175B1 (et) 2009-06-15
ATE304851T1 (de) 2005-10-15
NO20021860D0 (no) 2002-04-19
UA74347C2 (uk) 2005-12-15
NO20021860L (no) 2002-05-21
IS2196B (is) 2007-01-15
WO2001028558A1 (en) 2001-04-26
CN1382048A (zh) 2002-11-27
SI1274427T1 (sl) 2006-02-28
EP1274427A1 (en) 2003-01-15
NZ518155A (en) 2004-07-30
JP2003512327A (ja) 2003-04-02
AU782866B2 (en) 2005-09-01
MY131971A (en) 2007-09-28
DE60022789D1 (de) 2006-02-02
DE60022789T2 (de) 2006-06-22
EP1274427B1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
MY131971A (en) Formulation of substituted benzimidazoles
UY27320A1 (es) Nuevas composiciones farmacéuticas
SE0101387D0 (sv) Novel compounds
TR200103474T2 (tr) Bileşimlerin anti-bakteriyel madde olarak yeni kullanımları
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
TNSN03110A1 (en) Azaindoles.
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
TR200003158T2 (tr) Jelleşebilen farmasötik bileşimler
EA200400777A1 (ru) Фармацевтические композиции соединения платины
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ATE306917T1 (de) Pharmazeutische zusammensetzung mit 2-(4- isobutylphenyl) propionsäure
SE0201659D0 (sv) Modified release pharmaceutical formulation
SE0402762D0 (sv) Indazole sulphonamide derivatives
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
AR034370A1 (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
EA200001061A1 (ru) Фармацевтическая композиция
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
SE0102440D0 (sv) New compound
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
SE0002476D0 (sv) New compounds
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ES2069040T3 (es) Solucion estable de hipoclorito de sodio.
DE60031699D1 (de) Hydroxyacetamidobenzolsulfonamidderivate